Gilead’s Anti-HIV Drug Royalties Worth $1 Billion, US Tells Jury

Gilead Sciences Inc. should pay the US as much as $1 billion in total royalties for Truvada and Descovy’s infringement of three patents related to an HIV-prevention regimen, the government said as a closely watched trial between former research partners went to the jury.

After delivering closing arguments Monday, each side asked Judge Maryellen Noreika to rule on a spate of disputed issues from the bench in the US District Court for the District of Delaware. Jurors began deliberating less than a week after the trial opened in Wilmington.

The US Health and Human Services Department sued Gilead and its ...